Full-Time
Updated on 3/14/2025
Develops therapies for neurological disorders
No salary listed
Senior, Expert
San Diego, CA, USA
Hybrid model requires this role to work in the office three days per week on average.
Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1993
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement
Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).
Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.
US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.
"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."
Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia